AWARDDEFINITIVE CONTRACTOther than small business
Definitive contract 75F40120C00176THE LELAND STANFORD JUNIOR UNIVERSITY
Overview
Award facts
- Net obligations
- $3.96M
- $3,956,154of $3.96M potential value
- Outlays (paid to date)
- $3.85M
- $3.85M paid of $3.96M obligated$3,850,803
- Period of performance
- Sep 30, 2020 to Mar 30, 2026
- Ended
- Modifications
- 11
- Latest action Sep 15, 2025
- Contract type
- Definitive contract
- PIID 75F40120C00176
Contract value is the most the government could spend; obligations are what it has legally committed; outlays are what it has actually paid.
Description of requirement
PATHOLOGY AND PATHOGENESIS OF CORONAVIRUS INFECTIONS IN ANIMAL MODELS
Dates and value
- Award date
- Signed on Sep 30, 2020
- Potential end of performance
- Mar 29, 2026
- Current value
- $3,956,154Base and exercised options
- Potential value (if all options are exercised)
- $3,956,154
Obligations by fiscal year of action
- FY2024: $1,205,654
- FY2023: $700,000
- FY2021: $500,000
- FY2020: $1,550,500
Total across 4 fiscal years: $3,956,154
Source: Federal Procurement Data System contract actions as published by SAM.gov and USAspending.gov; latest action recorded Sep 15, 2025. View on USAspending · Recipient on SAM.gov
Recipient
LocationSTANFORD, CA
UEIHJD6G4D6TJY5
CAGE code1KN27
Business sizeOther than small businessSize at award, per the contracting officer
Organization typeCorporate tax exempt
Parent companyTHE LELAND STANFORD JUNIOR UNIVERSITY
Business types and certifications
Nonprofit organizationEducational institutionTax-exempt corporation
As represented in SAM.gov at the time of the action.
Subcontracting network
The prime, the subcontractors on this award, and their own subcontractors.
Agency and place
Awarding and funding
- Awarded by
- Department of Health and Human Services
- Food And Drug Administration
- FDA OFFICE OF ACQ GRANT SVCS
- Funded by
- Department of Health and Human Services
- Food And Drug Administration
- FDA OFFICE OF ACQ GRANT SVCS
- Funded from
- Foods; Human drugs; Devices and radiological health; Fda other activities (fda headquaters); Animal drugs and feed; Biologics; Coronavirus emergency funding supplementalProgram activities075-0600Federal accounts (agency financial reports)
Place of performance
- Place of performance
- Silver Spring, Montgomery County, Maryland 20993-0001
- Congressional district (place of performance)
- MD-08As reported at the time of the action
Classification and competition
Classification
- Product or service (PSC)
- B537SPECIAL STUDIES/ANALYSIS- MEDICAL/HEALTH (service)
Competition
- Extent competed
- Full and open competitionA
- Solicitation procedures
- Negotiated proposal/quoteNP
- Set-aside
- No set-aside used
- Contract pricing
- Cost no feeS
- Offers received
- 10
Solicitation and notices
- Solicitation ID
- FDABAA-20-00123
- Solicitation date
- Sep 25, 2020
- Notices
- Combined Synopsis/Solicitation posted Jan 17, 2020
- Combined Synopsis/Solicitation posted Jan 17, 2020
- Combined Synopsis/Solicitation posted Sep 27, 2019
Contract details
- Subcontracting plan
- Individual subcontract planF
- Cost Accounting Standards clause
- Yes - CAS clause includedY
- Certified cost or pricing data
- Yes
- Commercial procedures
- Commercial products/services procedures not usedD
- Government-furnished property
- Transaction does not use GFE/GFPN
- Bundled requirement
- Not bundledH
- Consolidated requirement
- Not consolidatedD
- Undefinitized action (terms not final)
- No
- Multi-year contract
- No
- Performance-based service acquisition
- Yes - service where PBA is used.Y
Linked notices
Notice | Notice ID | Type | Link | Posted |
|---|---|---|---|---|
Transaction history
Modification history
- Base award
- Sep 30, 2020Base obligation at award: $1,550,500
- Latest action
- Sep 15, 2025 — Other administrative actionModification P00011; administrative: no change in scope or value
- Latest substantive action
- Aug 19, 2024 — Supplemental agreement (within scope)Modification P00009; obligation change +$1,205,654
- Actions by type
- Base award1
- Other administrative action6
- Supplemental agreement (within scope)5
Similar awards
PIID | Match | Awardee |
|---|---|---|
All contract data
All contract data
Every other field reported for this award, as of its latest reported action
Competition
- Evaluation preference
- No preference used
- Local area set-aside
- No
- Synopsized publicly (SAM.gov / FedBizOpps)
- Yes
- Simplified procedures for commercial items
- No
- A-76 (FAIR Act) action
- No
Pricing and financing
- Paid by purchase card
- No
Socio-economic and policy
- Inherently governmental functions
- Closely associated,critical functionsCL,CT
- Recovered materials and sustainability
- No clauses included and no sustainability includedC
- EPA-designated product
- Not requiredE
- Clinger-Cohen Act planning (IT)
- No
Place and origin
- Domestic or foreign entity
- U.S. owned businessA
- Country of product or service origin
- United statesUSA
- Place of manufacture
- Not a manufactured end productC
Structure
- Award or IDV
- Award
- Award type
- Definitive contractD
- Awarding agency code
- 7500
- Awarding sub-tier code
- 7524
- Contracting office code
- 75F401
- Transactions recorded under this award key
- 12
Funding
- Funding agency code
- 7500
- Funding sub-tier code
- 7524
- Funding office code
- 75F401
- Treasury accounts
- 075-2020/2020-0600-000
- 075-2023/2023-0600-000
- 075-2024/2024-0600-000
- 075-X-0600-000
- Object classes
- 25.1: Advisory and assistance services
- 25.5: Research and development contracts
- Disaster or emergency funding (DEFC)
- L: Emergency P.L. 116-123
- N: Emergency P.L. 116-136
- Q: Not Designated Nonemergency/Emergency/Disaster/Wildfire Suppression
- U: Emergency P.L. 116-260
- COVID-19 supplemental obligations
- $2,378,037
- COVID-19 supplemental outlays
- $2,372,872